Resultados de la búsqueda 91-100 of 2940 for SC

  1. Oncología (médica) - Ensayos clínicos

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  2. Dermatología - Ensayos clínicos

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  3. Cirugía maxilar - Médicos y departamentos - Mayo Clinic

    Bagheri SC, ed. Mandibular orthognathic surgery. In: Clinical Review of Oral and Maxillofacial Surgery. 3rd ed. Elsevier; 2025. https://www.clinicalkey.com ...

  4. Dermatología - Ensayos clínicos

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  6. Dermatología - Ensayos clínicos

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  7. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  8. Dermatología - Ensayos clínicos

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  9. Cirugía maxilar - Médicos y departamentos - Mayo Clinic

    Bagheri SC, ed. Mandibular orthognathic surgery. In: Clinical Review of Oral and Maxillofacial Surgery. 3rd ed. Elsevier; 2025. https://www.clinicalkey.com ...

  10. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...